Shares of Surgery Partners, Inc. (NASDAQ:SGRY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ten research firms that are covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $36.56.
A number of analysts have weighed in on the stock. Bank of America initiated coverage on shares of Surgery Partners in a report on Monday, December 16th. They set a “buy” rating and a $30.00 target price on the stock. Royal Bank of Canada dropped their price objective on shares of Surgery Partners from $49.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 20th. JPMorgan Chase & Co. lowered their target price on Surgery Partners from $38.00 to $28.00 and set a “neutral” rating for the company in a report on Tuesday, December 3rd. UBS Group began coverage on Surgery Partners in a research report on Monday, October 14th. They set a “buy” rating and a $38.00 price target on the stock. Finally, KeyCorp initiated coverage on Surgery Partners in a research report on Friday, October 11th. They set a “sector weight” rating for the company.
Read Our Latest Stock Report on SGRY
Hedge Funds Weigh In On Surgery Partners
Surgery Partners Stock Up 1.6 %
NASDAQ:SGRY opened at $25.70 on Friday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.66 and a current ratio of 1.80. The company has a market capitalization of $3.27 billion, a price-to-earnings ratio of -53.54, a price-to-earnings-growth ratio of 17.66 and a beta of 2.60. Surgery Partners has a one year low of $19.50 and a one year high of $35.29. The stock has a 50-day simple moving average of $21.71 and a 200 day simple moving average of $27.00.
Surgery Partners (NASDAQ:SGRY – Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.06). The firm had revenue of $770.40 million during the quarter, compared to analyst estimates of $768.99 million. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. Surgery Partners’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.15 EPS. Sell-side analysts predict that Surgery Partners will post 0.71 EPS for the current fiscal year.
Surgery Partners Company Profile
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Featured Stories
- Five stocks we like better than Surgery Partners
- Are Penny Stocks a Good Fit for Your Portfolio?
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- Financial Services Stocks Investing
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.